Zandra K. Klippel

发表

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

M. Dimopoulos, X. Leleu, O. Landgren, 2020, The Lancet.

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

N. Burwick, P. Becker, W. Bensinger, 2015, Bone Marrow Transplantation.

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

M. Dimopoulos, D. Siegel, R. Orlowski, 2020, Cancer medicine.

Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series

D. Siegel, D. Vesole, J. Richter, 2018, Leukemia & lymphoma.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

M. Dimopoulos, D. Siegel, X. Leleu, 2019 .

Value of incorporating newly identified risk factors into risk prediction for chemotherapy‐induced febrile neutropenia

Leila Family, C. Chao, Lanfang Xu, 2018, Cancer medicine.

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

E. Warren, P. Robbins, L. Voong, 2014, Gene Therapy.

A Phase III, Randomized, Double‐Blind, Placebo‐Controlled Trial of Pegfilgrastim in Patients Receiving First‐Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti‐VEGF Evaluation Study (PAVES)

P. Gibbs, J. Jassem, Y. Hotko, 2017, Clinical colorectal cancer.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

G. Lyman, J. Crawford, T. Osslund, 2017, Supportive Care in Cancer.

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies

Hong Wang, J. Page, M. Reiner, 2016, Supportive Care in Cancer.

Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice.

Su-Jau Yang, Leila Family, C. Chao, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma

M. Dimopoulos, J. H. Lee, P. Moreau, 2019 .

A Randomized, Single‐Blind Study Evaluating the Effect of a Bone Pain Education Video on Reported Bone Pain in Patients with Breast Cancer Receiving Chemotherapy and Pegfilgrastim

C. Maxwell, P. K. Morrow, M. Reiner, 2018, Pain management nursing : official journal of the American Society of Pain Management Nurses.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation

D. Coffey, P. Becker, A. Cowan, 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

R. Rifkin, J. Berenson, J. Shah, 2019, Clinical lymphoma, myeloma & leukemia.

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora.

Leila Family, C. Chao, Lie-Hong Chen, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

R. Orlowski, E. Zamagni, J. Minařík, 2024, The New England journal of medicine.

Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335)

R. Rifkin, J. Berenson, J. Shah, 2015 .